Journal of perinatology : official journal of the California Perinatal Association · 2026
Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stoeckel Ashley, Soule-Albridge Erin, Feldman Henry A, Sola-Visner Martha, Davenport Patricia
Аннотация
OBJECTIVE: Significant variability exists in the indications for and dosing of cryoprecipitate transfusions. We examined cryoprecipitate transfusions in neonates with a focus on indications, dosing, and the incidence of multi-donor exposure.
STUDY DESIGN: In this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected.
RESULTS: In total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved.
CONCLUSION: Significant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.
STUDY DESIGN: In this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected.
RESULTS: In total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved.
CONCLUSION: Significant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.